"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial looking at 2 different combinations of chemotherapy for small cell lung cancer
This trial was comparing a combination of gemcitabine and carboplatin with a combination of cisplatin and etoposide for small cell lung cancer.
Doctors often use chemotherapy to treat small cell lung cancer. This is usually a combination of a
In this trial, researchers were comparing this standard treatment with a combination of the platinum drug carboplatin and another drug called gemcitabine.
The aims of the trial were to find out
- If gemcitabine and carboplatin (GC) worked as well as cisplatin and etoposide (PE)
- Whether this new combination of drugs caused fewer side effects
Summary of results
The trial team found that GC worked as well as PE and caused fewer side effects.
The trial recruited 241 people with small cell lung cancer. Half had gemcitabine and carboplatin. The other half had cisplatin and etoposide.
The average length of time that people lived without any signs of the cancer growing was
- 5.9 months for people who had GC
- 6.3 months for people who had PE
Just under a third of people in each group lived for more than a year.
Two of the main side effects were hair loss and sickness. Both of these were more common in people who had PE.
Another side effect was a drop in the number of blood cells. This was more common in people who had GC. A drop in the number of blood cells leads to an increased risk of infection and bleeding problems. But people in the GC group did not actually have any more infections or bleeding problems than the people in the PE group.
So, the trial team found that GC worked as well as PE and caused less sickness and hair loss.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Robin Rudd
London Lung Cancer Group
National Institute for Health Research Cancer Research Network (NCRN)